Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Hillhouse Capital, Decheng Capital Lead $60m Series B Round In Us Dna Sequencing Platform Developer Omniome – China Money Network
Venture Capital

Hillhouse Capital, Decheng Capital Lead $60m Series B Round In Us Dna Sequencing Platform Developer Omniome – China Money Network

by chinamoneynetwork.com posted 1year ago 276 views
Hillhouse Capital and Chinese healthcare-focused investment firm Decheng Capital have led a US$60 million series B found in San Diego-based DNA sequencing platform developer Omniome, Inc. New investors including Lam Research Capital, Nan Fung Life Sciences, and existing investors including ARCH Venture Partners, Domain Associates, Biomatics Capital Partners and Altitude Life Science Ventures, also participated in the round, according to Omniome’s announcement. Founded in 2013, Omniome develops a DNA sequencing platform with its Sequencing By Binding™ (SBB™) technology.

In this article